Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Unicycive Therapeutics, Inc. (UNCY) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Unicycive is a clinical-stage biotechnology company developing therapies for kidney diseases, and its filings offer structured insight into the progress of oxylanthanum carbonate (OLC) and UNI-494, as well as its capital markets activities and corporate governance.
Investors can review Form 8-K current reports where Unicycive discloses material events such as receipt of a Complete Response Letter for the OLC New Drug Application, updates from FDA Type A meetings, NDA resubmission timing, reverse stock split implementation, at-the-market equity offering amendments, preliminary financial information, and Nasdaq listing compliance. Certain 8-Ks also reference press releases on financial results, clinical data publications, and legal proceedings, including a purported securities class action related to public statements about the OLC NDA.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide broader detail on Unicycive’s kidney disease pipeline, risk factors, research and development spending, general and administrative expenses, and descriptions of oxylanthanum carbonate and UNI-494, including orphan drug designation for prevention of delayed graft function in kidney transplant patients. These periodic filings also summarize the company’s status as an emerging growth company and its listing on the Nasdaq Capital Market under the symbol UNCY.
On Stock Titan, AI-powered tools can help interpret lengthy filings by highlighting key sections on regulatory milestones, capital structure changes such as reverse stock splits, at-the-market programs, and disclosed cash positions and runway commentary. Users can quickly locate discussions of OLC’s regulatory path, UNI-494 patents and designations, and updates that management reports through 8-Ks and other forms, enabling a more efficient review of Unicycive’s SEC reporting history.
Unicycive Therapeutics, Inc. reported that director Gaurav Aggarwal resigned from its Board of Directors effective April 6, 2026.
The company stated that his resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices and expressed gratitude for his service.
Unicycive Therapeutics reported narrower losses for the year ended December 31, 2025 and highlighted regulatory progress for its lead kidney-disease drug candidate. Research and development spending fell to $9.1 million from $20.0 million as major clinical work wound down, while general and administrative costs rose to $20.4 million from $12.1 million due to consulting, professional services, and commercial launch preparation.
Net loss attributable to common stockholders improved to $26.6 million, or $1.67 per share, from $37.8 million, or $5.65 per share, helped by lower R&D and a favorable warrant liability revaluation that turned other income to $3.0 million from a $4.6 million expense. As of March 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, and the company states it can fund planned operations into 2027. Management noted that the FDA has accepted its New Drug Application resubmission for oxylanthanum carbonate (OLC) for hyperphosphatemia in dialysis patients, with the potential for approval and launch later in 2026.
Unicycive Therapeutics’ annual report outlines its kidney-focused drug pipeline, regulatory progress, and commercial plans. The company’s lead candidate, oxylanthanum carbonate (OLC), targets hyperphosphatemia in dialysis patients and is being reviewed via the 505(b)(2) pathway. After a Complete Response Letter tied to a third-party manufacturer, Unicycive resubmitted its OLC NDA in December 2025; the FDA accepted it as a Class II resubmission with a new PDUFA target action date of June 29, 2026. The report describes positive Phase 2 tolerability data and bioequivalence to Fosrenol, along with a concentrated U.S. launch strategy focused on large dialysis organizations and high-prescribing nephrologists. A second program, UNI-494 for acute kidney injury and delayed graft function, has orphan drug designation but further development has been deprioritized while the company focuses on OLC commercialization.
Unicycive Therapeutics, Inc. has a new large shareholder disclosure. RA Capital Management, its RA Capital Healthcare Fund and principals Peter Kolchinsky and Rajeev Shah report beneficial ownership of 2,385,279 shares of Unicycive common stock, representing 9.99% of the class as of December 31, 2025.
The position comes through Tranche A, B and C warrants exercisable into preferred stock series that are convertible into common shares, all subject to a 9.99% beneficial ownership blocker. The filers certify the holdings are not for the purpose of changing or influencing control of Unicycive.
Unicycive Therapeutics received an updated ownership disclosure showing that Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 2,281,040 shares of common stock, or 9.99% of the company, as of December 31, 2025.
This stake includes 1,341,838 shares that may be acquired within sixty days through the exercise of convertible securities. The reporting persons share voting and dispositive power over all reported shares and report no sole voting or dispositive authority.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. A fund advised by Nantahala, Blackwell Partners LLC – Series A, has rights to dividends and sale proceeds on more than five percent of the outstanding common stock reported here.
Octagon Capital Advisors and related funds report a sub-5% passive stake in Unicycive Therapeutics, Inc. They disclose beneficial ownership of 1,000,000 shares of Unicycive common stock, representing 4.7% of the class as of a 21,491,396-share base reported on November 12, 2025.
The shares are held through Octagon Investments Master Fund LP and Octagon Biotech Opportunities Fund I LP, with Octagon Capital Advisors LP as investment manager and Dr. Ting Jia as control person. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Unicycive.
Integrated Core Strategies (US) LLC, together with Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, reports beneficial ownership of 1,172,667 shares of Unicycive Therapeutics, Inc. common stock, representing 5.5% of the outstanding class as of 01/16/2026. The filing shows no sole voting or dispositive power, with all voting and disposal rights reported as shared among the reporting persons.
The shares are held through entities subject to voting control and investment discretion by Millennium Management LLC and other affiliated investment managers, with Millennium Group Management LLC as managing member and Mr. Englander as sole voting trustee of its managing member. The reporting parties state that the securities were not acquired and are not held for the purpose of changing or influencing control of Unicycive and are instead reported on a passive basis under Schedule 13G.
Unicycive Therapeutics, Inc. has amended its existing at-the-market equity program with Guggenheim Securities to expand potential common stock sales. The company previously could sell shares of common stock with an aggregate offering price of up to $50,000,000 under its Form S-3 shelf registration. As of November 14, 2025, Amendment No. 1 to the Sales Agreement increases the maximum aggregate offering price that may be sold in the ATM offering to $100,000,000. The ATM offering allows the company to issue and sell shares from time to time under its effective shelf registration statement and related sales agreement prospectus, as supplemented.
Unicycive Therapeutics (UNCY) filed a Form 8-K stating it issued a press release announcing financial results for the three months ended September 30, 2025 and provided a business update. The press release is furnished as Exhibit 99.1. The company notes the information under Item 2.02, including Exhibit 99.1, is being furnished and not filed under Section 18 of the Exchange Act.
Unicycive Therapeutics filed its Q3 2025 10-Q, showing larger resources and continued R&D investment. Cash and cash equivalents were $42.7 million as of September 30, 2025, up from $26.1 million at year-end 2024, reflecting equity activity. Total assets were $50.6 million and stockholders’ equity was $37.5 million.
The company reported a Q3 2025 net loss of $6.0 million and a nine‑month net loss of $11.9 million. Operating expenses were $7.3 million in Q3 (R&D $3.0 million; G&A $4.4 million). Other income benefited from a $1.1 million non‑cash gain from the change in fair value of warrant liabilities in Q3, and $9.8 million for the nine months.
Operating cash outflows were $23.3 million for the nine months. To fund operations, Unicycive sold 8,046,736 shares via its sales agreement with Guggenheim at an average price of $4.94, paying $1.2 million in commissions and receiving approximately $38.6 million in net proceeds. A 1‑for‑10 reverse stock split became effective in June 2025. 20,850,363 shares were outstanding as of September 30, 2025, and 21,491,396 as of November 12, 2025.